AI assistant
BOIRON — Earnings Release 2013
Apr 23, 2013
1161_iss_2013-04-23_493f91a3-b71e-47a3-8b81-af04c42a8bf0.pdf
Earnings Release
Open in viewerOpens in your device viewer
2013 FIRST QUARTER ACTIVITY
(Unaudited data)
| thousands of euros | 2012 | 2013 | Variation at current exchange rates |
Variation at constant exchange rates |
|---|---|---|---|---|
| France | 74,188 | 84,720 | +13.6% | +13.6% |
| International : | 54,904 | 73,751 | +34.3% | +35.0% |
| Incl. Europe excluding France | 41,807 | 54,334 | +30.0% | +30.4% |
| Incl. North America | 10,285 | 15,562 | +51.3% | +52.6% |
| Incl. Other countries | 2,812 | 3,855 | +37.1% | +39.4% |
| Group Total | 129,092 | 158,021 | +22.4% | +22.7% |
| thousands of euros | 2012 | 2013 | Variation at current exchange rates |
Variation at constant exchange rates |
|---|---|---|---|---|
| Non-proprietary Homeopathic Medicines | 73,427 | 79,062 | +7.7% | +7.7% |
| OTC Specialties | 55,576 | 78,866 | +41.9% | +42.5% |
| Other | 0,089 | 0,093 | +4.5% | +3.4% |
| Group Total | 129,092 | 158,021 | +22.4% | +22.7% |
HIGHLIGHTS OF FIRST QUARTER
- The growth in sales revenues was highlighted by a high level of worldwide pathology and the impact of the prices increase in 2012 on certain non-proprietary homeopathic medicines in France. Such prices increase, for the most part, will only impact the first two months of 2013.
- On March 31st 2013, the group's cash balance amounted to €121.5 million versus €94.7 million on December 31st 2012, which is linked to the increase of the business activity during the fourth quarter of 2012.
- The U.S. subsidiary signed a settlement agreement aimed to put an end to the legal proceeding relating to Children's Coldcalm® medicine in California.
That agreement, which is subject to the court's approval, provides for:
- a commitment to change the advertising and packaging within a time limit of 24 months from the court final approval,
- bearing the legal expense of the opposing party,
- the reimbursement, based solely on a claim-made process, to consumers who purchased the medicine in California.
It should be noted that a provision of 1 million US dollars was recorded for this litigation in 2011, which we still believe corresponds to the risk incurred.
• Based on first-quarter performance, the group confirms its target of further increases in business and profitability in 2013.
Next updates:
May 23, 2013 at 10:30 am, at Boiron headquarters : 20 rue de la Libération, 69110 Sainte-Foy-lès-Lyon : Mixed General Meeting. June 5, 2013, after the approval by the Mixed shareholders' Meeting, proposed dividend (0.90 € per share) will be paid out. August 29, 2013, after the close of the stock market, publication of 2013 half-year financial information. Financial information manager: Philippe MONTANT Contact for financial information: Véronique BOUSCAYROL Investor relations: +33 (0) 4.78.45.63.43 - e-mail: [email protected] ISIN Code: FR0000061129 (BOI) - Bloomberg : BOI FP - Reuters : BOIR.PA The group's financial information is online at : www.boiron.com